Journal Articles

Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinvovial^®) vs hylan G-F20 (Synvisc^®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study.

Journal: Osteoarthritis and Cartilage

Authors: Pavelka K, Uebelhart D.

Synovial (GELSYN-3) was found to be equivalent to higher molecular weight Synvisc in efficacy and safety. Although not statistically significant, there were fewer treatment-related adverse events were seen with Synovial (GELSYN-3).

Full article available at Elsevier.

View GELSYN-3 Videos

DUROLANE, GELSYN-3 and SUPARTZ FX are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g., acetaminophen. Risks include general knee pain and pain at the injection site.

View Use and Important Safety Information at: DUROLANE.com, GELSYN3.com, and SUPARTZFX.COM

Summary of Indications for Use:
DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Cookie name	Description	Cookie Type	Expiration
_ga	Registers a unique ID that is used to generate statistical data on how the visitor uses the website.	Statistic	2 years
_gat	Used by Google Analytics to throttle request rate	Statistic	1 day
_gid	Registers a unique ID that is used to generate statistical data on how the visitor uses the website.	Statistic	1 day
Facebook	Used to measure the effectiveness of Facebook ads, define custom audiences for ad targeting, dynamic ads campaigns, and analyze the effectiveness of the website’s conversion funnels. Uses first-party and third-party cookies.	Marketing	180 days
spu_closing	Stores information if a popup window was closed.	Marketing	30 days

Journal Articles

Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinvovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study.

Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinvovial^®) vs hylan G-F20 (Synvisc^®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study.